Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Cloretazine receives Fast Track designation from FDA
April 6th, 2004
Vion Pharmaceuticals, Inc., (VION) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for Cloretazine (VNP40101M) in relapsed or refractory acute myeloid leukemia (AML). The FDA's fast track programs are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Alan Kessman, chief executive officer, stated, "Our preclinical and initial clinical data indicate that Cloretazine (VNP40101M) has the potential to improve treatment for patients with relapsed or refractory...
Source: Cancer Weekly (2004-04-06)
|
